Aliases & Classifications for Phototoxic Dermatitis

MalaCards integrated aliases for Phototoxic Dermatitis:

Name: Phototoxic Dermatitis 12 15
Dermatitis, Phototoxic 44 73
Photosensitisation Reaction 12
Photosensitive Dermatitis 12
Photosensitiveness 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4407
MeSH 44 D017484
NCIt 50 C4816
SNOMED-CT 68 53597009 84326006
UMLS 73 C0162830

Summaries for Phototoxic Dermatitis

MalaCards based summary : Phototoxic Dermatitis, also known as dermatitis, phototoxic, is related to photoparoxysmal response 1 and cutaneous lupus erythematosus, and has symptoms including photophobia An important gene associated with Phototoxic Dermatitis is IER3IP1 (Immediate Early Response 3 Interacting Protein 1), and among its related pathways/superpathways are Staphylococcus aureus infection and amb2 Integrin signaling. The drugs Aminolevulinic acid and Racepinephrine have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and brain.

Related Diseases for Phototoxic Dermatitis

Diseases related to Phototoxic Dermatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 252)
# Related Disease Score Top Affiliating Genes
1 photoparoxysmal response 1 33.3 IER3IP1 TRIM21
2 cutaneous lupus erythematosus 30.3 ICAM1 TRIM21
3 trichothiodystrophy 1, photosensitive 12.6
4 photosensitive epilepsy 12.5
5 trichothiodystrophy 2, photosensitive 12.4
6 trichothiodystrophy 3, photosensitive 12.4
7 cutaneous photosensitivity and colitis, lethal 12.3
8 hair defect-photosensitivity-intellectual disability syndrome 12.2
9 hair defect with photosensitivity and mental retardation 12.0
10 chronic actinic dermatitis 12.0
11 ataxia-photosensitivity-short stature syndrome 12.0
12 trichothiodystrophy 4, nonphotosensitive 11.8
13 trichothiodystrophy 5, nonphotosensitive 11.7
14 trichothiodystrophy 6, nonphotosensitive 11.7
15 ataxia-telangiectasia-like disorder 2 11.6
16 cockayne syndrome 11.6
17 xeroderma pigmentosum, variant type 11.6
18 kindler syndrome 11.5
19 porphyria, congenital erythropoietic 11.5
20 protoporphyria, erythropoietic, 1 11.4
21 coproporphyria, hereditary 11.4
22 porphyria variegata 11.4
23 protoporphyria, erythropoietic, x-linked 11.4
24 actinic prurigo 11.2
25 xeroderma pigmentosum, complementation group d 11.2
26 jeavons syndrome 11.2
27 cerebrooculofacioskeletal syndrome 1 11.0
28 hartnup disorder 11.0
29 xeroderma pigmentosum, complementation group f 11.0
30 uv-sensitive syndrome 1 11.0
31 uv-sensitive syndrome 2 11.0
32 uv-sensitive syndrome 3 11.0
33 protoporphyria, erythropoietic, 2 11.0
34 uv-sensitive syndrome 11.0
35 corneal dystrophy, lattice type i 10.9
36 prolidase deficiency 10.9
37 cockayne syndrome a 10.9
38 nonphotosensitive trichothiodystrophy 10.9
39 chd2 myoclonic encephalopathy 10.9
40 cockayne syndrome type i 10.9
41 cockayne syndrome type ii 10.9
42 cockayne syndrome type iii 10.9
43 epilepsy 10.7
44 dermatitis 10.5
45 lupus erythematosus 10.4
46 porphyria 10.3
47 epilepsy, idiopathic generalized 10 10.2
48 smith-lemli-opitz syndrome 10.2
49 opitz gbbb syndrome, type i 10.2
50 epilepsy, idiopathic generalized 10.1

Graphical network of the top 20 diseases related to Phototoxic Dermatitis:



Diseases related to Phototoxic Dermatitis

Symptoms & Phenotypes for Phototoxic Dermatitis

UMLS symptoms related to Phototoxic Dermatitis:


photophobia

Drugs & Therapeutics for Phototoxic Dermatitis

Drugs for Phototoxic Dermatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 465)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 106-60-5 137
2
Racepinephrine Approved Phase 4,Not Applicable,Early Phase 1 329-65-7 838
3
Epinephrine Approved, Vet_approved Phase 4,Not Applicable,Early Phase 1 51-43-4 5816
4
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 1 564-25-0 54671203
5
Lymecycline Approved, Investigational Phase 4 992-21-2 5280963
6
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
7
Azithromycin Approved Phase 4 83905-01-5 55185 447043
8
Verteporfin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129497-78-5
9
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 347396-82-1 459903
10
Methoxsalen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 298-81-7 4114
11
Zinc Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 7440-66-6
12
Titanium dioxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 13463-67-7
13
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 1406-66-2 14986
14
Hydroxocobalamin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 13422-51-0 11953898 44475014
15
Copper Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 7440-50-8 27099
16
Nicotinamide Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 98-92-0 936
17
Iodine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7553-56-2 807
18
Methylcobalamin Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 13422-55-4
19
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
20
Flavin Mononucleotide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 146-17-8 643976
21
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 124-94-7 31307
22
Ethanol Approved Phase 4,Phase 3,Phase 2,Not Applicable 64-17-5 702
23
Benzophenone Approved Phase 4,Not Applicable 119-61-9 3102
24
Iron Approved Phase 4,Phase 3,Phase 1,Not Applicable 7439-89-6 23925
25
Oxybenzone Approved, Investigational Phase 4,Not Applicable 131-57-7 4632
26
Avobenzone Approved, Investigational Phase 4 70356-09-1
27
Zinc oxide Approved Phase 4 1314-13-2
28
Interferon beta-1b Approved Phase 4 145155-23-3
29
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
30
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
31
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
32
Selenium Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 7782-49-2
33
Stavudine Approved, Investigational Phase 4,Phase 2,Phase 3 3056-17-5 18283
34
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-21-8 3385
35
Rifampicin Approved Phase 4,Phase 3 13292-46-1 5458213 5381226
36
Imiquimod Approved, Investigational Phase 4,Not Applicable 99011-02-6 57469
37
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 59-02-9 14985
38
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-30-3 6037
39
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-43-8, 70-16-6 1130
40
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 83-88-5 493570
41
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 1406-16-2
42
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 1,Not Applicable 59-67-6 938
43
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 11103-57-4, 68-26-8 445354
44
Cyanocobalamin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68-19-9 44176380
45
Vitamin C Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-81-7 5785 54670067
46
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 65-23-6 1054
47
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 1,Not Applicable 50-14-6 5280793
48 Tocotrienol Investigational Phase 4,Phase 3,Phase 1,Not Applicable 6829-55-6
49
Cobalamin Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 13408-78-1 6438156
50 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 586)
# Name Status NCT ID Phase Drugs
1 Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate Unknown status NCT01491711 Phase 4 Methylaminolevulinate PDT in 2 sessions;Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
2 Clinical, Microbiological and Biochemical Effects of the Antimicrobial Photodynamic Therapy Unknown status NCT01532674 Phase 4
3 Time to Eradication of Mycoplasma Genitalium and Chlamydia Trachomatis After Treatment Commenced Unknown status NCT01661985 Phase 4 Azithromycin;Doxycycline;lymecycline
4 Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between MAL Cream and ALA Gel Unknown status NCT02647151 Phase 4 METHYLAMINOLEVULINATE HYDROCHLORIDE;AMINOLEVULINIC ACID HYDROCHLORIDE
5 Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration Unknown status NCT00813891 Phase 4 Ranibizumab;Ranibizumab;Ranibizumab
6 A Study to Determine the Safety and Sensitizing Potential of HAT1 Topical Products Using Skin Sensitivity Patch Tests Completed NCT03406117 Phase 4 HAT1
7 Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL) Completed NCT02464709 Phase 4 Aminolevulinic Acid;Methyl 5-aminolevulinate
8 Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses Completed NCT03327831 Phase 4 Aminolevulinic Acid
9 Daylight-PDT for AKs: Comparing Two Photosensitizers (BF-200 ALA and MAL) Completed NCT01893203 Phase 4 BF-200 ALA cream;MAL cream
10 Photodynamic Therapy During Supportive Periodontal Therapy Completed NCT02666573 Phase 4
11 Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy According to the Laser Density for Actinic Keratosis Completed NCT03731988 Phase 4 lidocaine/prilocaine (5%) application;MAL application
12 PRO With Luxerm® in the Field Treatment of Thin and Non-hyperkeratotic Non-pigmented AK Completed NCT03511326 Phase 4 Methyl Aminolaevulinate 16% Cream
13 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Completed NCT02685592 Phase 4 5-aminolevulinic acid nanoemulsion
14 Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times Completed NCT02622594 Phase 4 Aminolevulinic Acid (ALA)
15 Photodynamic Therapy (PDT) With Levulan and Blue Light for the Treatment of Actinic Cheilitis Completed NCT02409732 Phase 4 aminolevulinic acid hydrochloride
16 Aflibercept in Polypoidal Choroidal Vasculopathy Completed NCT02120950 Phase 4 Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
17 Study of Photodynamic Therapy (PDT) in Patients With Central Serous Chorioretinopathy (CSC) Completed NCT01574430 Phase 4
18 Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT) Completed NCT01000636 Phase 4
19 PDT Study for Exudative AMD With PCV Completed NCT00331435 Phase 4
20 Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A Completed NCT00221039 Phase 4 Methoxsalen+ECP
21 Photodynamic Therapy in Occult-Only Lesions (POOL) Completed NCT00135837 Phase 4 Verteporfin for injection
22 Ultraviolet and UV-Visible Light Photoprotection for the Treatment of Melasma Completed NCT01695356 Phase 4 290-400 nm sunscreen;290-800 nm sunscreen
23 Efficacy and Safety of Probiotic Treatment as a Supportive Therapy in Eradication of H. Pylori Completed NCT01969331 Phase 4
24 Efficacy of Fish Oil in Multiple Sclerosis Completed NCT01842191 Phase 4
25 Dermal Penetration of the Titanium Dioxide in Anthelios SX SPF40 Cream Completed NCT01021787 Phase 4 Titanium dioxide
26 Clinical Trial to Evaluate the Efficacy and Safety of 'URSA SOFT CAP. (UDCA-003)' in Fatigue Patients With Liver Dysfunction Completed NCT02415777 Phase 4 Ursodeoxycholic acid, thiamine, riboflavin
27 Mesoglycan, Vascular Reactivity and Metabolic Syndrome Completed NCT02254850 Phase 4 Mesoglycan;Mesoglycan;Placebo;Placebo
28 The Effect of Low Furanocoumarin Grapefruit Hybrid Juice Consumption on Midazolam Pharmacokinetics Completed NCT02117869 Phase 4
29 Visual Outcome in Patients With Symptomatic Macular PCV Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy. Completed NCT01846273 Phase 4 Ranibizumab;Verteporfin PDT;Sham PDT
30 Corneal Thickness Changes During Corneal Collagen Cross-linking With Ultraviolet-A Irradiation and Riboflavin Completed NCT01485211 Phase 4 cross-linking with hypo-osmolar riboflavin
31 Effectiveness of Varenicline: Testing Individual Differences Completed NCT01228175 Phase 4 Placebo;Varenicline
32 Effect of Prenatal Nutritional Supplementation on Birth Outcome in Hounde District, Burkina Faso Completed NCT00909974 Phase 4
33 Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment Completed NCT00680498 Phase 4 Ranibizumab;Ranibizumab plus Photodynamic therapy
34 Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy Completed NCT00674323 Phase 4 Verteporfin Photodynamic Therapy;Ranibizumab
35 Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration Completed NCT00473642 Phase 4 Ranibizumab;Verteporfin;Verteporfin
36 Lactate Metabolism Study in HIV Infected Persons Completed NCT00202228 Phase 4 cofactor supplementation (thiamine, riboflavin, L-carnitine)
37 Initial Versus Delayed PDT Combination With Conbercept in PCV Recruiting NCT02821520 Phase 4 conbercept
38 Photodynamic Therapy for Papulopustular Rosacea Recruiting NCT02075671 Phase 4 Aminolevulinic acid topical solution 20%
39 Investigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics Recruiting NCT03012529 Phase 4 Rifampin;Riboflavin Placebo
40 Cohort Study of the Clinical Course of Macular Diseases in Kagawa Recruiting NCT02321267 Phase 4 ranibizumab, aflibercept, pegaptanib, verteporphin
41 Daylight-PDT With MAL for AK and Photodamaged Skin Active, not recruiting NCT02736760 Phase 4 Daylight photodynamic therapy using Methylaminolevulinate (MAL)
42 Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy Active, not recruiting NCT02495181 Phase 4 IVT Aflibercept; Verteporfin PDT;IVT Aflibercept; Sham PDT
43 IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis Active, not recruiting NCT02281682 Phase 4 Imiquimod;5-fluorouracil;Ingenol mebutate
44 Epi-On Corneal Crosslinking for Keratoconus Enrolling by invitation NCT03245853 Phase 4 Riboflavin 5'-Phosphate
45 Aminolevulinic Acid-photodynamic Therapy for Facial Actinic Keratosis Treatment and Prevention Not yet recruiting NCT03642535 Phase 4 ALA
46 Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD) Terminated NCT00134667 Phase 4 Photodynamic Therapy (PDT) with Visudyne (verteporfin);Macugen (pegaptanib sodium)
47 PUVA Versus PUVA + IFN Alpha 2a in Mycosis Fungoides Terminated NCT00630903 Phase 4 PUVA (8MOP + UVA) + IFN;PUVA (8-MOP + UVA)
48 Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients Terminated NCT01538901 Phase 4 imiquimod 5% cream
49 Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy Terminated NCT01203878 Phase 4 Photodynamic therapy;Imiquimod
50 Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration Terminated NCT00423189 Phase 4 Ranibizumab (Lucentis);0.5mg ranibizumab

Search NIH Clinical Center for Phototoxic Dermatitis

Cochrane evidence based reviews: dermatitis, phototoxic

Genetic Tests for Phototoxic Dermatitis

Anatomical Context for Phototoxic Dermatitis

MalaCards organs/tissues related to Phototoxic Dermatitis:

41
Skin, Bone, Brain, Liver, Colon, Prostate, Bone Marrow

Publications for Phototoxic Dermatitis

Articles related to Phototoxic Dermatitis:

(show all 11)
# Title Authors Year
1
Images in clinical medicine. Phototoxic dermatitis. ( 25099580 )
2014
2
Nine case series with phototoxic dermatitis related to Chenopodium album. ( 22241627 )
2012
3
Phototoxic dermatitis due to Chenopodium album in a child. ( 21854411 )
2011
4
Phototoxic dermatitis due to Chenopodium album in a mother and son. ( 15982237 )
2005
5
Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma. ( 15097966 )
2004
6
An outbreak of phototoxic dermatitis due to limes. ( 3812457 )
1987
7
Outbreak of phototoxic dermatitis from limes--Maryland. ( 3925324 )
1985
8
Phototoxic dermatitis from Sclerotinia sclerotiorum infected celery. ( 6540157 )
1984
9
Phototoxic dermatitis caused by celery infected by Sclerotinia sclerotiorum. ( 6228376 )
1983
10
Inhibition of ultraviolet and phototoxic dermatitis in the mouse. ( 82323 )
1978
11
Phototoxic dermatitis in a horse. (A case report). ( 5198169 )
1970

Variations for Phototoxic Dermatitis

Expression for Phototoxic Dermatitis

Search GEO for disease gene expression data for Phototoxic Dermatitis.

Pathways for Phototoxic Dermatitis

Pathways related to Phototoxic Dermatitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.07 C3 ICAM1
2 10.94 ICAM1 KNG1
3
Show member pathways
10.78 LDHA LDHC
4 10.46 LDHA LDHC
5
Show member pathways
9.7 LDHA LDHC

GO Terms for Phototoxic Dermatitis

Biological processes related to Phototoxic Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 interferon-gamma-mediated signaling pathway GO:0060333 9.26 ICAM1 TRIM21
2 pyruvate metabolic process GO:0006090 9.16 LDHA LDHC
3 carboxylic acid metabolic process GO:0019752 8.96 LDHA LDHC
4 acute inflammatory response to antigenic stimulus GO:0002438 8.62 ICAM1 IL31RA

Molecular functions related to Phototoxic Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor GO:0016616 8.96 LDHA LDHC
2 L-lactate dehydrogenase activity GO:0004459 8.62 LDHA LDHC

Sources for Phototoxic Dermatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....